News | January 06, 2026
Wegovy pill marks first GLP-1 weight-loss medicine in oral form
The approval introduces a needle-free alternative to injectable GLP-1 therapies
The approval introduces a needle-free alternative to injectable GLP-1 therapies
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
CystoSmart, an AI tool designed to detect bladder tumors during screening and surveillance cystoscopy, is brand-agnostic and works with flexible, rigid, and single-use scopes
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
The approval is supported by data from three pivotal clinical trials
Elanco expects Befrena to launch in the US in the first half of 2026
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
Motiva, SmoothSilk, Round and Ergonomix implants represent the latest in plastic surgery innovation
Subscribe To Our Newsletter & Stay Updated
